Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Work In Process (2021 - 2024)

Historic Work In Process for Apellis Pharmaceuticals (APLS) over the last 4 years, with Q1 2024 value amounting to $106.2 million.

  • Apellis Pharmaceuticals' Work In Process rose 11901.96% to $106.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $106.2 million, marking a year-over-year increase of 11901.96%. This contributed to the annual value of $82.9 million for FY2023, which is 5327.63% up from last year.
  • As of Q1 2024, Apellis Pharmaceuticals' Work In Process stood at $106.2 million, which was up 11901.96% from $82.9 million recorded in Q4 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Work In Process peaked at $106.2 million during Q1 2024, and registered a low of $10.1 million during Q4 2021.
  • In the last 4 years, Apellis Pharmaceuticals' Work In Process had a median value of $48.4 million in 2023 and averaged $48.1 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Work In Process skyrocketed by 43789.02% in 2022 and then surged by 5327.63% in 2023.
  • Over the past 4 years, Apellis Pharmaceuticals' Work In Process (Quarter) stood at $10.1 million in 2021, then surged by 437.89% to $54.1 million in 2022, then skyrocketed by 53.28% to $82.9 million in 2023, then grew by 28.02% to $106.2 million in 2024.
  • Its Work In Process was $106.2 million in Q1 2024, compared to $82.9 million in Q4 2023 and $52.1 million in Q3 2023.